astellas Logo
Astellas Pharma GmbH
Document: /presse/artikel.html?press_id=136
Datum: 12.12.2018

Cookie Hinweis

Auf unserer Webseite setzen wir Cookies ein, also kleine Textdateien, die auf Ihrem Rechner abgelegt werden und die Ihr Browser speichert. Indem Sie fortfahren, akzeptieren Sie dies.

Die Verwendung von Cookies kann jederzeit durch entsprechende Einstellungen in Ihrem Browser verhindert werden. Bitte beachten Sie, dass die Blockierung von Cookies die volle Nutzbarkeit und die korrekte Anzeige der Webseite verhindern kann. Weitere Informationen finden Sie in unseren Datenschutzbestimmungen.




Pressemeldungen von Astellas Pharma zum Unternehmen und zu unseren Produkten.


30. 3. 2011. Staines, London and San Francisco, USA, 30 March 2011 -- Astellas Pharma Europe Ltd. and Medivation, Inc. today announced treatment of the first patient in the TERRAIN trial, a Phase 2 comparison of the investigational drug MDV3100, a triple-acting, oral androgen receptor antagonist, with bicalutamide, a commonly used non-steroidal anti-androgen, for the treatment of advanced prostate cancer in patients who have progressed while on LHRH analogue therapy or following surgical castration.

“Given the novel mechanism of MDV3100, this study has the potential to answer fundamental clinical questions about continued androgen receptor signalling in patients with progressive prostate cancer despite castrate levels of testosterone,” said Professor Axel Heidenreich, Principal Investigator of the TERRAIN trial, from Universitätsklinikum der RWTH in Aachen, Germany, “We look forward to the results of this important trial.”

The TERRAIN Phase 2 trial is expected to enroll approximately 370 patients in Europe and North America. The primary endpoint of the trial is progression-free survival.

“MDV3100 has been shown in preclinical studies to provide more complete suppression of the androgen receptor signalling pathway than existing anti-androgens and the TERRAIN study provides the opportunity to investigate this finding further in a clinical setting,” said Lynn Seely, M.D., Chief Medical Officer of Medivation. “MDV3100 is currently in Phase 3 testing for advanced prostate cancer, but our goal is to determine if MDV3100 can benefit men with prostate cancer earlier in the course of the disease.”

“This is the first of two Phase 2 trials in earlier-stage disease that we and our partner Medivation will initiate this year to evaluate the potential benefit of MDV3100 in a broad spectrum of prostate cancer patients,” said Steven Ryder, M.D., President, Astellas Pharma Global Development. “The second of our new Phase 2 trials will study MDV3100 in an even earlier-stage population – hormone naïve prostate cancer patients who are indicated for androgen deprivation therapy. We expect to begin that trial in the first half of this year.”

MDV3100 Phase 3 Clinical Development Programme
In addition to the TERRAIN trial, MDV3100 is currently being evaluated in two global Phase 3 studies in patients with advanced prostate cancer.

The randomised, double-blind, placebo-controlled Phase 3 AFFIRM trial completed enrollment in November 2010. This trial of 1,199 patients with advanced prostate cancer who were previously treated with docetaxel-based chemotherapy is evaluating 160 mg/day of MDV3100 versus placebo. The primary endpoint is overall survival.

A second Phase 3 clinical trial of MDV3100 in advanced prostate cancer, the PREVAIL trial, is currently enrolling patients. This randomised, double-blind, placebo-controlled, multi-national trial of approximately 1,700 men with advanced prostate cancer who have not yet received chemotherapy is evaluating MDV3100 at a dose of 160 mg taken orally once daily plus standard of care versus placebo plus standard of care. The co-primary endpoints of the trial are overall survival and progression-free survival.

About the Medivation/Astellas Collaboration
In October 2009, Medivation and Astellas entered into a global agreement to jointly develop and commercialise MDV3100. The companies are collaborating on a comprehensive development programme that includes studies to develop MDV3100 across the full spectrum of advanced prostate cancer disease states. Subject to receipt of regulatory approval, the companies will jointly commercialise MDV3100 in the U.S. and Astellas will have responsibility for commercialising MDV3100 outside the U.S.. Medivation received a $110 million up-front payment upon entering into the collaboration agreement, and is eligible to receive up to $335 million in development milestone payments, up to $320 million in commercial milestone payments, 50% of profits on sales in the U.S., and tiered, double-digit royalties on sales outside the United States.

About MDV3100
MDV3100 is an investigational therapy in clinical development for advanced prostate cancer. In a Phase 1-2 trial in 140 patients with advanced prostate cancer published in The Lancet in April 2010, encouraging anti-tumour activity was noted with MDV3100 across endpoints. In preclinical experiments published in Science in April 2009, the triple-acting, oral androgen receptor antagonist provided more complete suppression of the androgen receptor pathway than bicalutamide, the most commonly used anti-androgen. MDV3100 slows growth and induces cell death in bicalutamide-resistant cancers via three complementary actions - MDV3100 blocks testosterone binding to the androgen receptor, impedes movement of the androgen receptor to the nucleus of prostate cancer cells (nuclear translocation) and inhibits binding to DNA. In the preclinical experiments published in Science, MDV3100 was superior to bicalutamide in each of these three actions.

About Prostate Cancer
Prostate cancer is the second most common non-skin cancer among men in the world, and it is the sixth leading cause of cancer death among men worldwide. Patients whose prostate tumours have stopped responding to, or are growing despite the use of active hormone treatment strategies are considered to have advanced prostate cancer. These patients have a poor prognosis and few treatment options.

This press release contains forward-looking statements, including statements regarding the continued clinical development of Medivation's product candidates, the therapeutic and commercial potential of MDV3100, the planned initiation of additional clinical trials and the continued effectiveness of, and continuing collaborative activities under, Medivation's collaboration agreements with Pfizer and Astellas, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause Medivation's actual results to differ significantly from those projected, including, without limitation, risks related to progress, timing and results of Medivation's clinical trials, including the risk that adverse clinical trial results could alone or together with other factors result in the delay or discontinuation of some or all of Medivation's product development activities, enrollment of patients in Medivation's clinical trials, partnering of Medivation's product candidates, including Medivation's dependence on the efforts of and funding by Astellas for the development of MDV3100, the achievement of development, regulatory and commercial milestones under Medivation's collaboration agreements, the manufacturing of Medivation's product candidates, the adequacy of Medivation's financial resources, unanticipated expenditures or liabilities, intellectual property matters, and other risks detailed in Medivation's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2010, filed on March 16, 2011 with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. Medivation disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release.

About Astellas Pharma Europe Ltd.
Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East and Africa, an R&D site and three manufacturing plants. The company employs approximately 3,900 staff across these regions. For more information about Astellas Pharma Europe, please visit

About Medivation, Inc.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at

Contacts for inquiries or additional information

Astellas Pharma Europe Ltd.
Corporate Communications
Mindy Dooa
Tel: +44 (0)1784 419408

Medivation, Inc.
Chief Business Officer
Patrick Machado
Tel: +1 415 829 4101